MINIRIN

AssetAlso called desmopressin, desmopressin acetate, STIMATE, DDAVP

Activates vasopressin V2 receptors to increase renal water reabsorption and reduce urine production.

Stage
Approved, not sold in the US
Modality
Peptide
Target
AVPR1A
6
Indications
40
Trials
3
Developers

Approved by the FDA on Sep 16, 2002 (NDA021333). Not sold in the US: Drugs@FDA marks every US product that holds it discontinued. FDA

Indications

6

3 more

In the full profile

  • Target and mechanism4
  • Owner and partners3
  • Trials40
  • Evidence for its targets4
  • Competitors7
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets